
|Articles|October 24, 2012
VMA treatment approved
The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
Last year in glaucoma at EnVision Summit 2025
3
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
4
Looking back at the 2025 EnVision Summit
5




























